Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 14/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614344 | 0.82 | TLR2 (0.43) | MEN1ALDH1A1HPGDKMT2ATLR2 | |
| SCHEMBL31614316 | 0.76 | NMBR (0.38) | MEN1ALDH1A1HPGDKMT2AP2RY12 | |
| SCHEMBL30852949 | 0.72 | GLO1 (0.40) | ALDH1A1P2RY12 | |
| SCHEMBL22472269 | 0.71 | THRA (0.46) | MEN1KMT2A | |
| SCHEMBL20503189 | 0.68 | THRA (0.41) | MEN1KMT2A | |
| SCHEMBL22472270 | 0.68 | THRA (0.51) | — | |
| SCHEMBL23387116 | 0.68 | SMPD1 (0.49) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL19549612 | 0.67 | ELANE (0.43) | MEN1KMT2A | |
| SCHEMBL23387400 | 0.67 | ESR1 (0.47) | — | |
| SCHEMBL20518462 | 0.67 | MGLL (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025122535-A2 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | AMGEN INC. (US) | 2025-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188118-A1 | LIQUID PHASE PEPTIDE SYNTHESIS METHODS | VIP, RNGTT, SSU72 | MEN1 1270/4885ALDH1A1 3744/4885HPGD 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.